MMJ PhytoTech appoints pharmaceutical experts to drive expansion
Medical Cannabis company MMJ PhytoTech (ASX:MMJ) has added to its senior management and advisory personnel Stanislav Sologubov as Chief Executive Officer of Satipharm Switzerland and John Hollister as a strategic pharmaceutical consultant.
The key appointments are in line with MMJ’s intended evolution towards a pharmaceutical business model in which the company plans to commercialise Medical Grade Cannabis and high potential cannabis based therapeutics products to the international market and in line with medical cannabis laws.
Managing Director of MMJ, Andreas Gedeon had the following to say in the announcement to the market:
“We are very pleased to be appointing two highly regarded healthcare industry professionals to assist with our transition into a leading pharmaceutical company.
“We view our expansion into key European markets as a significant near-term value driver for the business, and the appointments of Stanislav and John respectively, are a core component of this strategy.
“The Board is...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin